RC
IMA

Rangeley Capital’s ImageneBio Inc IMA Stock Holding History

Rangeley Capital’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
32,590
+14,346
+79% +$93.1K 0.16% 98
2025
Q4 		$126K Buy
18,244
+3,244
+22% +$24.1K 0.1% 101
2025
Q3 		$122K Buy
+15,000
New +$199K 0.11% 107

Other funds holding IMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rangeley Capital's IMA Position: Q1 2026 in Review

Rangeley Capital increased its ImageneBio Inc (IMA) stake by 79% in Q1 2026, buying an estimated $93.1K and bringing the position to 32,590 shares worth $163K. The position accounts for 0.16% of the portfolio, ranked #98.

Rangeley Capital first reported a position in IMA in Q3 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold IMA as of Q1 2026.

  • Rangeley Capital held 32,590 shares of ImageneBio Inc worth $163K as of Q1 2026.
  • Rangeley Capital bought 14,346 ImageneBio Inc shares in Q1 2026, an estimated $93.1K.
  • ImageneBio Inc made up 0.16% of Rangeley Capital's portfolio in Q1 2026, its #98 holding.
  • Rangeley Capital first reported a position in ImageneBio Inc in Q3 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held ImageneBio Inc as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.